Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric Cancer
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. Materials and Methods: The study patients were chemotherapy-naïve patients (＞ 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. Results: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2∼6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4∼12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. Conclusion: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer. (Cancer Res Treat. 2007;39:99-103)
Abstract
Purpose: We investigated the efficacy and safety of a combination of oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) as first-line palliative chemotherapy for elderly patients with metastatic or recurrent gastric cancer. Materials and Methods: The study patients were chemotherapy-naïve patients (＞ 65 years old) with histologically confirmed, metastatic or recurrent gastric cancer. Chemotherapy consisted of oxaliplatin 100 mg/m2 and FA 100 mg/m2 (2-hour infusion), and then 5-FU 2400 mg/m2 (46-hour continuous infusion) every 2 weeks. Results: A total of 37 patients were studied between April 2004 and October 2006. Of the 34 evaluable patients, none achieved a complete response (CR) and 14 achieved a partial response (PR), resulting in an overall response rate of 41.2%. The median time to progression (TTP) was 5.7 months (95% CI: 4.2∼6.3 months) and the median overall survival (OS) was 9.8 months (95% CI: 4.4∼12.0 months). The main hematologic toxicities were anemia and neutropenia, which were observed in 56.7% and 32.4% of the patients, respectively. Grade 3/4 neutropenia was observed in 8.1% of the patients. None of the patients experienced febrile neutropenia. Peripheral neuropathy occurred in 35.1% of the patients and all were grade 1/2. Conclusion: This oxaliplatin/5-FU/FA regimen showed good efficacy and an acceptable toxicity profile in elderly patients with metastatic or recurrent gastric cancer. (Cancer Res Treat. 2007;39:99-103)
참고문헌 (25)
- Pisters PWT, "Cancer of the stomach", pp.909~944 (2005), Philadelphia: Lippincott Williams & Wilkins
- Shin HR, "Nationwide cancer incidence in Korea, 1999∼2001; first result using the national cancer incidence database", 37, pp.325~331 (2005)
- Pyrhonen S, "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer", 71, pp.587~591 (1995)
- Murad AM, "Rausch M. Modified therapy with 5-fluorouracil and methotrexate in advanced gastric cancer. Cancer. 1993;72", pp.37~41
- Glimelius B, "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", 8, pp.163~168 (1997)
- Webb A, "Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicn and methotrexate in advanced esophagogastric cancer", 15, pp.261~267 (1997)
- Waters JS, "Long-term survival after epirubicin, cisplatin, and fluorouracil for gastric cancer: results of a randomized trial", 80, pp.269~272 (1999)
- Vanhoefer U, "Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group", 18, pp.2648~2657 (2000)
- Moiseyenko VM, "Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combinded with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric carcinoma (MGC)", 23, pp.308~ (2005)
- Louvet C, "Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients", 20, pp.4543~4548 (2002)
- Lordick F, "Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer", 93, pp.190~194 (2005)
- Al-Batran SE, "Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer", 22, pp.658~663 (2004)
- Chao Y, "Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer", 91, pp.453~458 (2004)
- Bang YJ, "Phase II study of oxaliplatin, 5-fluorouracil and folinic acid in recurrent or metastatic gastric cancer", 21(109) (2002)
- Hutchins LF, "Underrepresentation of patients 65 years of age or older in cancer treatment trials", 341, pp.2061~2067 (1999)
- Lewis JH, "Participation of patients 65 years of age or older in cancer clinical trials", 21, pp.1383~1389 (2003)
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", 92, pp.205~216 (2000)
- Kranenbarg EK, "Gastric cancer in the elderly", 5, pp.384~390 (1998)
- Wilke H, "et al. High dose folinic acid", etoposide[DOI]
- Fedeli A, "leucovorin 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients", pp.72~4
- Cascinu G, "Intensive weekly chemotherapy for elderly gastric cancer patients using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and gluthatione with the support of G-CSF", 81, pp.32~35 (1995)
- Di Bartolomeo M, "Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy", 52, pp.41~44 (1995)
- Hartung G, "Combination of bolus 5-fluorouracil, folinic acid and mitomycin-C in advanced gastric cancer: results of a phase II trial", 23, pp.444~447 (2000)
- Graziano F, "A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer", 89, pp.1428~1432 (2003)
- Santini D, "Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial", 6, pp.125~131 (2006)